The aim of the work was to understand the toxicity, physically significant descriptors and pharmaceutically relevant properties of some imidazoles obtained from the open sources that may found to be active against tuberculosis. At present five azoles were modeled for the prediction and calculation of descriptors that were carried out by means of computational approach [1] .
Introduction
Current treatment of tuberculosis (TB) is based on drugs that are more than 40 years old.
Drugs that are active against resistant forms of TB are less potent, more toxic, and need to be taken for a long time (18 months). The recent emergence of virtually untreatable extensively drug-resistant TB (XDR-TB) poses a new threat to TB control worldwide. Furthermore, effective treatment of TB in persons co infected with HIV is complicated due to drug-drug interactions.
Shorter and simpler regimens that are safe, well tolerated, effective against drug-susceptible and drug-resistant TB, appropriate for joint HIV-TB treatment, and amenable to routine programmatic conditions are needed urgently.
The recent treatment of tuberculosis
WHO recommends the universal use of the 6-month rifampin throughout Short Course Chemotherapy (SCC) regimen for the treatment of drug-susceptible TB. For MDR-TB and XDR-TB are, however, complicated due to long duration, high toxicity, poor tolerance, and high cost, resulting in poor outcomes. But found that some of the nitroimidazoles belonging to a novel class of antimicrobacterial agents are active against drug susceptible and drug resistant organism for the treatment of MDRTB [2] .
At present a study of ADME (Absorption Distribution Metabolism Elimination) of certain azoles was analyzed for predicting the ADME properties prior to expensive experimental procedures, such as HTS, can eliminate unnecessary testing on compounds that are doomed to fail, it can also focus lead optimization efforts to enhance the desired ADME properties. Finally, incorporating ADME predictions as a part of the development process will result in lead compounds that are more likely to exhibit satisfactory ADME performances during clinical trials Nearly 40% of drug candidates fail in clinical trials due to poor ADME properties. These late-stage failures contribute significantly to the skyrocketing cost of new drug development. The ability to detect problematic candidates early will dramatically reduce the amount of wasted time and resources, and streamline the overall development process.
Materials and methods
We used the following molecules for the toxicity prediction.
2 3 4 5 Method
The molecules obtained from the open source was modeled, minimized and were uploaded for the descriptor and toxicity prediction and the results were tabulated in the respective tables 1, 2 and 3.
Results and Discussions
The results for the each molecule are tabulated. * indicates the violation of the rules. From the above results the azoles have been analyzed in such a way that the molecule 2 to5
were violating two of the parameter in the principal descriptors and predictions for properties as mentioned in the tables. Also, molecule 1 was violating the parameter solute Electron Affinity in principal descriptors. The molecules similar to the known compounds were also tabulated. These molecules are showing more drug like properties with less toxicity, for which they can be screened against any of the targets in Mycobacterium Tuberculosis in designing the future TB drug.
